AMENDMENT NO. 10 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Trial Agreement • March 7th, 2019 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 10 to Clinical Trial Agreement (the “Amendment” or “Amendment 10”) is entered into as of October 15, 2018 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
